Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | CA-4948 |
Trade Name | |
Synonyms | CA4948|CA 4948 |
Drug Descriptions |
CA-4948 inhibits IRAK4, thereby blocking TLR and IL-1R signaling, potentially resulting in tumor regression (PMID: 33335659). |
DrugClasses | IRAK4 Inhibitor 6 |
CAS Registry Number | 1801343-74-7 |
NCIT ID | C148455 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CA-4948 | CA-4948 | 0 | 3 |
CA-4948 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | CA-4948 Fluorouracil Leucovorin Nivolumab Oxaliplatin | 0 | 1 |
CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab | CA-4948 Fluorouracil Leucovorin Oxaliplatin Pembrolizumab Trastuzumab | 0 | 1 |
CA-4948 + Ibrutinib | CA-4948 Ibrutinib | 0 | 0 |
CA-4948 + Idelalisib | CA-4948 Idelalisib | 0 | 0 |
CA-4948 + Pembrolizumab | CA-4948 Pembrolizumab | 0 | 1 |
CA-4948 + Venetoclax | CA-4948 Venetoclax | 0 | 0 |